Category Specific RSS

News

HeraMED and Telstra Health come together to launch remote maternity solution HeraCARE

Medical data and technology company HeraMED (ASX: HMD)’s subsidiary HeraCARE is gearing up for its soft launch with Telstra. It will soon be available to medical practices using Telstra Health’s MedicalDirector patient management software.

In November 2023, HeraMED initially announced its partnership with Telstra Health’s MedicalDirector platform, which serves GPs and healthcare professionals. HeraCARE is the first remote maternity solution to join the Telstra Health digital ecosystem. 

In 2022-2023, there were around 166 million GP patient encounters in Australia. According to the RACGP, pregnancy-related problems account for 2.7% of all GP–patient encounters, and of these encounters, 89.8% are for pregnancy or antenatal care. That makes it crucial for there to be an accessible GP solution for women. 

Telstra Health recently announced the soft launch at the Royal Australian College of General Practitioners (RACGP) Practice Owners Conference in Cairns, Australia. This initial step in the commercial rollout will focus on recruiting 5-10 GP clinics—“early adopters”—to integrate HeraCARE into MedicalDirector and GP workflows while optimising care and commercial models.

HeraMED CEO Anoushka Gungadin confirmed, “HeraCARE is a mum-centric solution and the partnership with Telstra Health allows us to expand access to care for many more mums, given the significant role GPs play in maternity, pregnancy and postpartum care. 

“Following integration and commercial rollout within this new ecosystem, we are targeting the onboarding of mums through GP practices by the end of calendar year 2024. This aligns with the four-point plan both for commercialisation and strategic partnership while redefining how maternity care is delivered and experienced.”

HeraMED is focused on the digital transformation of maternity care by changing the prenatal and postpartum experience with its hybrid maternity care platform. The Company’s proprietary offering, HeraCARE, offers a fully integrated maternal health ecosystem to deliver better care at a lower cost.

As of June 15, 2024, the number of accumulated mums on the HeraCARE platform reached 3,553 registered mums, up 12% since March. Recent growth can be primarily attributed to US-based channel partners e-Lovu Health and Perth-based private clinics Simply Women and JOGG.

In Q1 CY24, the Company’s cash balance was $217k. Its customer receipts totalled $14k, and it received $1.25 million in firm commitments at  2 cents per share.

HeraCARE, through MedicalDirector, will be available within Telstra Health’s recently launched Smart Connected Care ecosystem, which integrates into Telstra Health’s core platforms. This partnership with Telstra Health supports HeraMED’s commercialisation strategy to target the GP vertical, which plays a significant role in maternity, both prenatal and postpartum, to enhance the user’s maternity experience

HeraMED and Telstra Health will also jointly promote HeraMED’s integration into the Smart Connected Care ecosystem through education and marketing to existing and prospective users as part of the Smart Partner Marketing Plan.

On completion of the soft launch, HeraMED expects to market to the entire GP clinic customer base and onboarding mums through Telstra Health’s GP clinic practices by the end of calendar year 2024.

Alinda Gupta

Alinda is a Business Reporter for The Sentiment

Recent Posts

AML3D announces stronger FY26, with positive EBITDA reported in the second half

Adelaide-based metal printing group books record $12.5 million revenue and a record $78 million sales…

3 days ago

Refurbished tech gives Harris Technology a second life

Harris Technology has found a higher-margin growth engine in an unlikely place: the market for…

4 days ago

Imagion Biosystems Advances MagSense® Phase 2 Trial

Imagion Biosystems (ASX: IBX) is moving its MagSense® HER2 Imaging Agent Phase 1b/2 clinical trial…

1 week ago

Acrux-developed Menopause Hormone Therapy to enter Australian market

Acrux (ASX:ACR) is set to bring its transdermal Estradiol spray Lenzetto® to the Australian market…

3 months ago

Evion Expands Critical Minerals Push with Nevada Fluorspar Option

The race to secure Western-aligned critical minerals supply chains is accelerating as governments and industry…

4 months ago

Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone

Green360 Technologies (ASX:GT3) has taken a major step forward in the commercialisation of its low-carbon…

4 months ago